June 20, 2019

Investigational AMG 212 Shows Anti-cancer Activity in Advanced mCRPC in Phase 1 Trial

News

Amgen’s investigational therapy AMG 212 (pasotuxizumab) is safe, and showing therapeutic activity against metastatic castration-resistant prostate cancer (mCRPC) in a Phase 1 clinical trial, data show. This is the first ... Read more

August 4, 2017August 4, 2017

Amgen Asks FDA to Expand Prolia’s Approval to Include an Additional Osteoporosis Condition

News

Amgen has asked the U.S. Food and Drug Administration to expand its approval of the bone-building therapy Prolia (denosumab) to include an additional osteoporosis condition. The initial authorization covered men with metastatic prostate cancer who are ... Read more